Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Yellow fever vaccine (produced on serum-free Vero cells), Yellow fever vaccine, Yellow fever vaccine (live)
Yellow Fever · 2 trials · 4 indications
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dilution \[dil\]) in flavivirus non-immune participants (defined as those with YF antibodies \<10 \[1/dil\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).
GMTs of antibodies against each dengue virus serotype (parental strain) was assessed using the dengue plaque reduction neutralization test (PRNT).
Seropositivity against each dengue virus serotypes (parental strains) was assessed using the dengue PRNT. Seropositive participants were defined as the participants with neutralizing antibody titer \>=10 (1/dilution).
| Arm | Type | Description |
|---|---|---|
| CYD Dengue Vaccine Group | EXPERIMENTAL | Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month \[M\] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months). |
| Placebo Group | EXPERIMENTAL | Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months). |
| CYD Dengue vaccine: Group 1 | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months. |
| CYD Dengue vaccine: Group 2 | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months. |
| CYD Dengue and Yellow Fever vaccine: Group 3 | EXPERIMENTAL | Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0. |
| Yellow Fever vaccine: Group 4 | ACTIVE_COMPARATOR | Participants received single dose of YF vaccine at Day 0. |
| Name | Type | Description |
|---|---|---|
| Live, attenuated dengue serotype 1, 2, 3, and 4 virus | BIOLOGICAL | 0.5 mL, subcutaneous at age 12, 18, and 24 months |
| Yellow fever vaccine | BIOLOGICAL | 0.5 mL subcutaneous in the deltoid at age 12 to 13 months. |
| Measles, mumps, and rubella (MMR) vaccine | BIOLOGICAL | 0.5 mL, subcutaneous at age 12 to 13 months. |
| Pneumococcal Conjugated Vaccine | BIOLOGICAL | 0.5 mL, intramuscular at age 13 to 14 months |
| Hepatitis A Pediatric Vaccine | BIOLOGICAL | 0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months |
| Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine | BIOLOGICAL | 0.5 mL, intramuscular at age 19 to 20 months |
| Placebo (NaCl) | BIOLOGICAL | 0.5 mL, subcutaneous at age 12 to 13 months |
| Measles, mumps, and rubella vaccine | BIOLOGICAL | 0.5 mL, subcutaneous at age 13 to 14 months |
| Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Yellow Fever | BIOLOGICAL | 0.5 mL, Subcutaneous |
Inclusion Criteria: * Aged 12 to 13 months on the day of inclusion. * Born at full term of pregnancy (\>=37 weeks) and with a birth weight \>=2.5 kg as reported by the parent/legally acceptable representative. * Participant in good health, based on medical history and physical examination. * Partic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Danaher Corporation | DHR | 1 | - | Undisclosed |
Yellow Fever vaccine is used for immunization against yellow fever, a viral infection transmitted by mosquitoes. It is also being studied for use in dengue prevention. The vaccine is indicated for yellow fever immunization in adults and pediatric populations, and clinical trials are evaluating its safety and immunogenicity.
Sanofi (ticker: SNY) is developing the Yellow Fever vaccine. The vaccine is produced on serum-free Vero cells and is a live attenuated vaccine. Sanofi is conducting Phase 3 clinical trials to evaluate its safety and immunogenicity in various populations.
Yellow Fever vaccine is in Phase 3 clinical development. Multiple Phase 3 trials are ongoing or completed, including studies in adults and pediatric populations. The vaccine is investigational and not yet approved for widespread use.
Yellow Fever vaccine is being studied in several clinical trials. NCT07103148 is a Phase 3 study in pediatric populations in Honduras, Mexico, and Panama. NCT07002060 and NCT07222059 are Phase 3 studies in adults. NCT01488890 is a Phase 2 study evaluating immune response with a dengue vaccine.
Yes, Yellow Fever vaccine is also known as yellow fever vaccine (produced on serum-free Vero cells) and yellow fever vaccine (live). These names refer to the same investigational vaccine being developed by Sanofi for yellow fever immunization.
Yellow Fever vaccine is a live attenuated vaccine, meaning it contains a weakened form of the yellow fever virus. This stimulates the immune system to produce a protective response without causing the disease. It is being studied for its ability to provide immunity against yellow fever and potentially cross-protect against dengue.